부산대학교 도서관

Lung Cancer. 14(1):161-161

Kuiken MC; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Witsen M; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Voest EE; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Dijkstra KK; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE

L Angus; SM Wilting; J van Riet; M Smid; TG Steenbruggen; VC Tjan-Heijnen; M Labots; JM van Riel; HJ Bloemendal; N Steeghs; HJ van de Werken; MP Lolkema; EE Voest; A Jager; E Cuppen; S Sleijfer; JW Martens

Cancer Research. 79:GS1-07

van Renterghem AWJ; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.; Parra-Martinez M; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.; Witsen M; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.; Verkerk K; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.; Steur M; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.; Zeverijn LJ; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.; Dijkstra KK; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.; Akkari L; Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Division of Tumor Biology and Immunology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.; Voest EE; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address: e.voest@nki.nl.

Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE

Watterson A; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK.; Picco G; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK.; Veninga V; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.; Samarakoon Y; Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.; Cattaneo CM; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.; Vieira SF; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK.; Karakoc E; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK.; Bhosle S; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.; Battaglia TW; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Consonni S; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK.; Halim TYF; Cancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.; Voest EE; Department of Immunology and Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.; Garnett MJ; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK.; Coelho MA; Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK; Open Targets, Cambridgeshire, UK. Electronic address: matthew.coelho@sanger.ac.uk.

Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE

Verkerk K; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Haj Mohammad SF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.; Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Verbeek FAJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Timmer H; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.; van Maren MA; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Parra-Martinez M; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands.; Jansen AML; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, the Netherlands.; de Leng WWJ; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, the Netherlands.; Marchetti S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.; Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.

Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.; Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.; Zeverijn LJ; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Geurts BS; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Verkerk K; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Haj Mohammad SF; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.; van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Roepman P; Hartwig Medical Foundation, Amsterdam, the Netherlands.; de Leng WWJ; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, the Netherlands.; Jansen AML; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, the Netherlands.; van de Luijtgaarden ACM; Department of Medical Oncology, Reinier de Graaf Hospital, Delft, the Netherlands.; van Voorthuizen T; Department of Medical Oncology, Rijnstate, Arnhem, the Netherlands.; Buffart TE; Department of Medical Oncology, Amsterdam University Medical Center, location VUMC, Cancer Center, Amsterdam, the Netherlands.; Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.; Voest EE; Department of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.

Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE

Tan PB; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Verschoor YL; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; van den Berg JG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Balduzzi S; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Kok NFM; Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Ijsselsteijn ME; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.; Moore K; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Jurdi A; Natera Inc, Austin, TX, USA.; Tin A; Natera Inc, Austin, TX, USA.; Kaptein P; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; van Leerdam ME; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.; Haanen JBAG; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; de Miranda NFCC; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.; Schumacher TN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.; Wessels LFA; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.; Chalabi M; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.chalabi@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.chalabi@nki.nl.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE

Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Oncode Institute, Utrecht, the Netherlands. Electronic address: k.dijkstra@nki.nl.; Vendramin R; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Tumor ImmunoGenomics and Immunosurveillance Laboratory, University College London Cancer Institute, University College London, London, UK.; Karagianni D; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Immunology Unit, Immune Regulation and Tumor Immunotherapy Group, Research Department of Haematology, University College London Cancer Institute, London, UK.; Witsen M; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.; Gálvez-Cancino F; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Immunology Unit, Immune Regulation and Tumor Immunotherapy Group, Research Department of Haematology, University College London Cancer Institute, London, UK; Immune Regulation Laboratory, Centre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.; Hill MS; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Foster KA; Cancer Immunology Unit, Immune Regulation and Tumor Immunotherapy Group, Research Department of Haematology, University College London Cancer Institute, London, UK.; Barbè V; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Angelova M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Hynds RE; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Epithelial Cell Biology in ENT Research (EpiCENTR) Group, Developmental Biology and Cancer Department, Great Ormond Street UCL Institute of Child Health, University College London, London, UK.; Pearce DR; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Martínez-Ruiz C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Black JRM; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Huebner A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Pich O; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Rowan A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.; Augustine M; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Tumor ImmunoGenomics and Immunosurveillance Laboratory, University College London Cancer Institute, University College London, London, UK; Division of Medicine, University College London, London, UK.; Puttick C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Moore DA; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Department of Cellular Pathology, University College London Hospital, London, UK.; Liu LL; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Saghafinia S; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; van de Haar J; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.; Veeriah S; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Naceur-Lombardelli C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Toncheva A; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Bola SK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Immunology Unit, Immune Regulation and Tumor Immunotherapy Group, Research Department of Haematology, University College London Cancer Institute, London, UK.; Hiley CT; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK.; Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK; Department of Medical Oncology, University College London Hospitals, London, UK.; McGranahan N; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.; Litchfield K; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Tumor ImmunoGenomics and Immunosurveillance Laboratory, University College London Cancer Institute, University College London, London, UK.; Reading JL; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Pre-Cancer Immunology Laboratory, University College London Cancer Institute, London, UK.; Chain B; University College London Cancer Institute, London, UK; Division of Infection and Immunity, University College London, London, UK.; Quezada SA; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Cancer Immunology Unit, Immune Regulation and Tumor Immunotherapy Group, Research Department of Haematology, University College London Cancer Institute, London, UK. Electronic address: s.quezada@ucl.ac.uk.; Voest EE; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address: e.voest@nki.nl.; Swanton C; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Department of Medical Oncology, University College London Hospitals, London, UK. Electronic address: charles.swanton@crick.ac.uk.

Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE

Mimpen IL; Netherlands Cancer Institute, Amsterdam, Netherlands.; Battaglia TW; Netherlands Cancer Institute, Amsterdam, Netherlands.; Parra Martinez M; Netherlands Cancer Institute, Amsterdam, Netherlands.; Toner-Bartelds C; Netherlands Cancer Institute, Amsterdam, Netherlands.; Zeverijn LJ; Netherlands Cancer Institute, Amsterdam, Netherlands.; Geurts BS; Netherlands Cancer Institute, Netherlands.; Verkerk K; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.; Hoes LR; Netherlands Cancer Institute, Amsterdam, Netherlands.; van Renterghem AWJ; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.; Noe M; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Baltimore, MD, United States.; Hofland I; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.; Broeks A; Netherlands Cancer Institute, Amsterdam, Netherlands.; van der Noort V; Netherlands Cancer Institute, Amsterdam, Netherlands.; Stigter ECA; UMC Utrecht, Utrecht, Netherlands.; Gulersonmez CMC; UMC Utrecht, Utrecht, Netherlands.; Burgering BMT; University Medical Center Utrecht, Utrecht, Utrecht, Netherlands.; van Gogh M; University Medical Center Utrecht, Utrecht, Netherlands.; de Zoete MR; University Medical Center Utrecht, Utrecht, Netherlands.; Gelderblom H; Leiden University Medical Center, Leiden, Netherlands.; Dijkstra KK; Netherlands Cancer Institute, Amsterdam, Netherlands.; Wessels LFA; The Netherlands Cancer Institute, Amsterdam, NH, Netherlands.; Voest EE; Netherlands Cancer Institute, Amsterdam, Netherlands.

Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE

Weeber, Fleur; van de Wetering, Marc; Hoogstraat, Marlous; Dijkstra, Krijn K.; Krijgsman, Oscar; Kuilman, Thomas; Gadellaa-van Hooijdonk, Christa G. M.; van der Velden, Daphne L.; Peeper, Daniel S.; Cuppen, Edwin P. J. G.; Vries, Robert G.; Clevers, Hans; Voest, EE

Proceedings of the National Academy of Sciences. 112:13308-13311

Taskén K; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. kjetil.tasken@medisin.uio.no.; Haj Mohammad SF; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. s.f.haj_mohammad@lumc.nl.; Fagereng GL; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. gfageren@ous-hf.no.; Sørum Falk R; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. rs@ous-hf.no.; Helland Å; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. aslaug.helland@medisin.uio.no.; Barjesteh van Waalwijk van Doorn-Khosrovani S; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands; CZ Health Insurance, Tilburg, The Netherlands. sahar.van.waalwijk@cz.nl.; Steen Carlsson K; Swedish Institute for Health Economics, Lund, Sweden. katarina.steen_carlsson@ihe.se.; Ryll B; Stockholm School of Economics Institute for Research, Stockholm, Sweden. Bettina.Ryll@hhs.se.; Jalkanen K; Clinical Trial Unit, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland. katriina.jalkanen@hus.fi.; Edsjö A; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Region Skåne, Malmö, Sweden. anders.edsjo@skane.se.; Russnes HG; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital, Oslo, Norway. h.e.g.russnes@medisin.uio.no.; Lassen U; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ulrik.lassen@regionh.dk.; Hallersjö Hult E; Stockholm School of Economics Institute for Research, Stockholm, Sweden. ebba.hallersjo.hult@hhs.se.; Lugowska I; Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland. Iwona.Lugowska@nio.gov.pl.; Blay JY; Centre Léon Bérard, Lyon, France. jean-yves.blay@lyon.unicancer.fr.; Verlingue L; Centre Léon Bérard, Lyon, France. Loic.VERLINGUE@lyon.unicancer.fr.; Abel E; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. edvard.abel@vgregion.se.; Lowery MA; Trinity St James Cancer Institute, Trinity College, Dublin, Ireland. MLOWERY@tcd.ie.; Krebs MG; Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. matthew.krebs@nhs.net.; Staal Rohrberg K; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. kristoffer.staal.rohrberg@regionh.dk.; Ojamaa K; Hematology-Oncology Clinic at Tartu University Hospital, Tartu, Estonia. Kristiina.Ojamaa@kliinikum.ee.; Oliveira J; Instituto Português de Oncologia do Porto FG, Porto, Portugal. julio.oliveira@ipoporto.min-saude.pt.; Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. h.verheul@erasmusmc.nl.; Voest EE; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.voest@nki.nl.; Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. a.j.gelderblom@lumc.nl.

Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE

Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; van Berge Henegouwen JM; Department of Clinical Genetics, Erasmus Medical Center, Leiden, The Netherlands.; van der Wijngaart H; Department of Medical Oncology, GROW, Maastricht University Medical Center, Maastricht, The Netherlands.; Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; Spiekman IA; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.; Battaglia TW; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.; van Beek DM; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Jansen AM; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.; de Leng WW; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.; Broeks A; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Labots M; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.; van Herpen CM; Department of Medical Oncology, Radboud Medical Center, Nijmegen, The Netherlands.; Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.; Verheul HM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.; Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.; Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.

Publisher: John Wiley And Sons Country of Publication: England NLM ID: 0204634 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9896 (Electronic) Linking ISSN: 00223417 NLM ISO Abbreviation: J Pathol Subsets: MEDLINE

Molloy, TJ; Devriese, LA; Helgason, HH; Bosma, AJ; Hauptmann, M; Voest, EE; Schellens, JHM; van't Veer, LJ

Br J Cancer
British Journal of Cancer, vol 104, iss 12

de Mulder, PHM; Haanen, JBAG; Sleijfer, Stefan; Kruit, Wim; Gietema, JA; Richel, DJ; Groenewegen, G; Voest, EE; van den Eertwegh, AJM (Fons); Osanto, S; Jansen, RL; Mulders, PFA

Nederlands Tijdschrift voor Geneeskunde. 152(7):371-375

Haj Mohammad SF; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. s.f.haj_mohammad@lumc.nl.; Timmer HJL; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Zeverijn LJ; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Geurts BS; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Verkerk K; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Verbeek FAJ; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.; Voest EE; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.

Publisher: Medical Journals Sweden AB Country of Publication: Sweden NLM ID: 8709065 Publication Model: Electronic Cited Medium: Internet ISSN: 1651-226X (Electronic) Linking ISSN: 0284186X NLM ISO Abbreviation: Acta Oncol Subsets: MEDLINE

Spiekman IAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.; Geurts BS; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Zeverijn LJ; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; de Wit GF; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; van der Noort V; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands.; de Leng WWJ; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands.; Jansen AML; Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands.; Kusters B; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.; Beerepoot LV; Department of Internal Medicine, ETZ Hospital (Elisabeth-TweeSteden Ziekenhuis), Tilburg, The Netherlands.; de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.; de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands.; de Groot JWB; Isala Oncology Center, Isala, Zwolle, The Netherlands.; Hoeben A; Division of Medical Oncology, Department of Internal Medicine, GROW School of Oncology and Development Biology, Maastricht University Center+, Maastricht, The Netherlands.; Buter J; Department of Medical Oncology, Amsterdam University Medical Center, Location VuMC, Amsterdam, The Netherlands.; Gelderblom HAJ; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.; Voest EE; Oncode Institute, Utrecht, The Netherlands.; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam,The Netherlands.; Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.

Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Langenberg, M; Terhaard, CHJ; Hordijk, GJ; van Es, RJJ; Voest, EE

Clinical Otolaryngology. 29(6):729-734

Verkerk K; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands.; Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands. Electronic address: e.voest@nki.nl.

Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: In Process; MEDLINE

Zeverijn LJ; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Looze EJ; Division of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Thavaneswaran S; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.; van Berge Henegouwen JM; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.; Simes RJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.; Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Sjoquist KM; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.; van der Wijngaart H; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.; Sebastian L; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.; Geurts BS; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Lee CK; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.; de Wit GF; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Espinoza D; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.; Roepman P; Hartwig Medical Foundation, Amsterdam, The Netherlands.; Lin FP; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.; Jansen AML; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.; de Leng WWJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.; van der Noort V; Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Leek LVM; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; de Vos FYFL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.; van Herpen CML; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.; Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.; Verheul HMW; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.; Thomas DM; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.; Voest EE; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Center for Personalized Cancer Treatment, Rotterdam, The Netherlands.

Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE